ABSTRACT
Introduction
Melasma, also known as chloasma, is a common skin disorder characterized by acquired hyperpigmentation. Many patients with this condition prefer using herbal remedies instead of chemical agents. This study aims to review clinical trials conducted on the effectiveness of herbal remedies in treating melasma.
Methods
In this scoping review, we searched the PubMed, Scopus, Web of Science, Cochrane, SID, and Magiran databases until August 2024. We designed the search strategy using MeSH database keywords “melanosis,” “herbal medicine,” “plant extracts,” “complementary therapies,” “traditional medicine,” “Persian medicine,” “clinical trials,” and their Entry Terms. We then reviewed and summarized the relevant articles.
Results
We found a total of 21 clinical trials examining the effectiveness of herbal remedies in treating melasma. The literature review revealed that licorice, rhubarb, a mixture of melon seed and chickpea, sorrel, Aloe vera leaf gel, parsley, tomato, fern, olive, pine bark, and Indian gooseberry had positive effects in treating melasma. Licorice is the most extensively studied herbal remedy for melasma treatment. Some patients who used licorice, rhubarb, and parsley experienced redness and skin allergies.
Conclusion
Few studies have evaluated the effectiveness of herbal remedies in treating melasma. Further research, including clinical trials, systematic reviews, and meta‐analyses, is necessary to assess the efficacy of herbal remedies and natural products, as well as their potential adverse effects.
Keywords: clinical trial, complementary therapies, herbal medicine, melanosis, Persian medicine, review
1. Introduction
Melasma, or chloasma, is a common skin disorder characterized by acquired hyperpigmentation [1, 2]. It presents as irregular, symmetrical patches on the skin, ranging in color from reddish‐brown to blue‐gray, and can vary in size from small spots to larger, darker patches [2, 3]. Melasma primarily affects areas of the body that are more exposed to sunlight, with the face being the most commonly affected area [4]. Overall, about 1% of people in the general population have melasma. However, that number can rise to 9% to 50% in high‐risk groups [2]. Geographical and racial variations among individuals in different countries can account for these differences [1]. Women and individuals with darker skin tones are more likely to experience melasma [4].
The exact cause of melasma remains unknown; however, genetics and environmental factors are believed to play significant roles in its development [5, 6]. Genetic predisposition and family history are considered the most important factors contributing to melasma. Approximately 50% of melasma patients report a family history of the condition [7]. Additionally, melasma is more prevalent in women compared to men, with a relatively low incidence in males [8, 9].
Hormonal changes and exposure to ultraviolet (UV) radiation are key factors influencing melasma [4, 8]. Studies have strongly correlated the development of melasma with increased sunlight and UV radiation exposure [5, 10]. UV radiation and sunlight induce the production of free radicals through lipid peroxidation in cell membranes. These free radicals stimulate melanocytes to produce more melanin, leading to the formation of melasma and the darkening of the skin [11].
Several studies have proven the effects of hormones on the incidence of melasma [12, 13]. Pregnant women have a significantly higher risk of developing melasma compared to others. While the exact mechanism of melasma occurrence during pregnancy remains unknown, we have observed a natural increase in levels of estrogen, progesterone, and melanocyte‐stimulating hormones [13]. Additionally, endocrine diseases like thyroid disorders can also impact the incidence of melasma. Researchers have found a fourfold increase in melasma occurrence in patients with thyroid disorders [14]. Some medications, including cosmetic agents that increase the sensitivity of the skin to the sun and anticonvulsants, can also contribute to the development of melasma [15].
Melasma is typically categorized into four types based on the pigment pattern: epidermal (on the skin), dermal (subcutaneous), mixed, and type IV (most commonly seen in individuals with very dark skin color) [16].
Diagnosing melasma is usually straightforward in clinics due to visible symptoms such as brown spots on the skin [5, 17]. A more detailed examination using Wood's lamp light (300 to 400 nm) can confirm the diagnosis. Laboratory studies are generally not necessary for diagnosing this disease [17].
Despite the existence of effective treatments for controlling and improving melasma‐induced spots, treating this disease still presents a multitude of challenges. The use of topical hydroquinone cream, along with avoiding exposure to sunlight and estrogenic hormones, appears to be the best treatment option for these patients [17, 18]. Sunscreen products play a crucial role in the treatment of melasma, with sunscreens having an SPF greater than 50 showing significant effectiveness [17]. Sunscreens containing hydroquinone are particularly effective in preventing and treating melasma in susceptible individuals [19].
Nowadays, the first line of treatment for melasma involves the use of a topical combination cream that includes 4% hydroquinone, 0.05% tretinoin, and fluocinolone acetonide ointment 0.01% [19]. Additionally, studies have found that creams, lotions, and gels containing corticosteroids and tretinoin can help clarify skin discoloration [18, 19]. Other treatment options to reduce skin melanin include chemical skin peeling using glycolic acid and salicylic acid, laser therapy, and dermis super inflation [19]. However, it is important to note that some of these treatment methods, especially laser therapy, can lead to complications such as epidermal necrosis, increased pigmentation after inflammation, and hypertrophic scarring [20, 21]. Therefore, they should only be considered if the first line of treatment fails. In cases where complications are absent, second‐line treatment methods generally result in faster recovery compared to first‐line drugs [17, 19].
Due to the side effects associated with chemical drugs, such as skin inflammation and redness, as well as the bothersome skin stains caused by melasma, many patients have turned to herbal remedies for treatment [22, 23]. Surprisingly, there has been a lack of comprehensive reviews of clinical trials conducted on herbal remedies for melasma treatment. We aim to focus this scoping review on the efficacy of herbal remedies examined in clinical trials for melasma treatment.
2. Methods and Material
2.1. Study Design
This scoping review study aims to investigate the efficacy of herbal remedies in treating patients with melasma. For preparing this document, we used the PRISMA Extension for Scoping Reviews (PRISMA‐ScR) guideline.
2.2. Eligibility Criteria
We searched for relevant clinical trials using keywords, including “melanosis,” “herbal medicine,” “plant extracts,” “complementary therapies,” “traditional medicine,” “Persian medicine,” “clinical trials,” and their synonyms from Entry Terms of MeSH databases. The search was conducted without any time limit up until August 2024. We also excluded case reports, reviews, and letters to the editor.
2.3. Information Sources
The databases include PubMed, Scopus, Web of Science, Embase, Cochrane, and Persian‐language databases like SID and Magiran. Moreover, we used the Google Scholar search engine to complete our search process.
2.4. Search and Selection of Sources of Evidence
After creating the search syntax, two authors, M.M.P. and N.Y., participated in screening and selecting relevant articles from the extracted articles from the databases. This was done by reviewing the titles and abstracts of the articles.
2.5. Data Charting Process and Synthesis of Results
In the data charting process, M.M.P., N.S., R.J., and M.H. were involved in reviewing the selected articles, data extraction, and confirmation of the data. Then, M.M.P., R.J., A.M., and M.H. tried to summarize and organize the extracted data using a researcher‐made tabulated form.
2.6. Data Items
Documentation included details about the type of clinical trial, the plant used, the drug application method, the drug form, participant details, the outcomes and end‐point assessment tools, the study results, and any reported adverse effects of the prescribed medications.
2.7. Ethics Statement
The protocol for this study received approval from the Research Ethics Committee of Shiraz University of Medical Sciences (Ethics Code: IR.SUMS.MED.REC.1399.597).
3. Results
The search strategy led to the selection and review of 19 clinical trials, as shown in Table 1. The following section discusses the studied plants and the results of each article separately.
TABLE 1.
The clinical trials conducted on herbal remedies for the treatment of melasma.
| Authors (year) | Type | Total samplesize | Age (year) | Gender | Type of melasma | Herbal remedy | Form of prepared | Dosage | Control group | Follow‐up duration | Tools assessment | Outcome | Side effect |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hossein Matourian pour (2010) [24] | Clinical trial | 27 | 17–47 | 27F | Malar melasma | Licorice | Cream 4% | Licorice cream 4% Once a day | 4% hydroquinone cream | 8 W | mMASI score | Based on mMASI score the licorice extract has less effect than 4% hydroquinone | No complications occurred in the licorice 4% group |
| Mohamed Amer et al. (2000) [25] | Clinical trial | 20 | 18–40 | 20F | Epidermal melasma | Licorice | Cream 2% | Licorice cream 2% twice a day | Placebo cream | 4 W | Pigmentation intensity criteria | About 80% of the lesions treated with licorice had excellent response. This rate was 0% in the control group. | Erythema and sensitivity were observed in two patients using licorice |
| Zhang Hui et al. (2019) [22] | Clinical trial | 31 | 20–60 | 31 | Melasma | Rhubarb | Liquid base | Rhubarb plant (liquid base) twice a day | Liquid placebo | 8 W | Melanin and mexameter index | No significant difference was observed between placebo and rhubarb plant | In rhubarb group, two mild complications (skin allergy) were observed only |
| Marjan Mahjour et al. (2020) [26] | Clinical trial | 32 | > 18 | 32F | Melasma | Melon seeds and chickpeas Cicer arietinum L. and Cucumis melo seeds | Cream | Combination of melon seeds 5% and chickpeas 5% on a daily basis and 0.5 units of finger's head | 4% of hydroquinone | 12 W | MASI score | Both groups recovered significantly | No side effects |
| Clarisse G. Mendoza et al. (2014) [27] | Clinical trial | 45 | 18–60 | 45F | Epidermal and mixed melasma | Sorrel or Rumex Occidentalis | Cream | Sorrel cream 3% twice a day | 4% of hydroquinone | 8 W | MASI score | The reduction of pigmentation in mexameter and the decrease of MASI score were higher in patients in the hydroquinone group, but in the 8th week, the improvement rate of the sorrel group was significantly higher than the other group | No side effects |
| Farwa Naqvi et al. (2020) [28] | Clinical trial | 120 | 20–50 | 91F, 17M | Melasma | Aloe vera leaves | Gel | Aloe vera leaf gel every night | Phenylalanine gel 2% | 12 W | MASI score | The reduction of the MASI score was not significant in patients treated with Aloe vera gel, while the group treated with phenylalanine significantly improved | No side effects |
| Simin Shamsi Maimandi et al. (2016) [29] | Clinical trial | 40 | 20–40 | 40F | Melasma | Licorice | Cream | Licorice cream 4% twice a day | Placebo cream | 12 W | mMASI score | The mMASI score in the intervention group decreased from 2.7 ± 11.03 to 0.6 ± 41.41 and in the control group decreased from 2.9 ± 11.25 to 1.2 ± 37.2 | No side effects |
| Liza Afriliana et al. (2021) [30] | Clinical trial | 62 | 30‐55 | 62F | Melasma | Tomato | Extract | Supplements extracted from tomatoes once a day | Placebo | 12 W | mMASI score and rate of IL‐17 | The results of this study showed that the group that used tomato supplements had significantly decreased pigmentation and mMASI score | No side effects |
| Shamshad Akram et al. (2013) [31] | Clinical trial | 84 | 16–45 | 74F, 8M | Epidermal melasma | Licorice | Topical | Licorice 4% plus ascorbic acid 5% daily | Licorice 4% | 8 W | MASI score | The group that had used ascorbic acid along with licorice had improved and the severity of melasma or MASI score had decreased significantly | No side effects |
| Chi‐Lyuk Guo et al. (2018) [32] | Clinical trial | 40 | 25–65 | 37F, 3M | Melasma | Tropical fern or polypodium leucotomos | Capsule | Tropical fern supplement daily two or four capsules (240–480 mg) | Placebo (480 mg) | 12 W | mMASI score and quality of life criteria | mMASI score and quality of life criteria improved significantly in patients receiving equatorial fern supplement | No side effects |
| Julia De Toledo Bagatin et al. (2020) [33] | Clinical trial | 42 | 32–49 | 42F | Melasma | Olive | Oral and topical | Olive oil orally | Oral and topical placebo | 90 Days | mMASI score | There was no significant difference between the three groups in terms of mMASI score | No side effects |
| Ahmed et al. (2013) [34] | Clinical trial | 33 | 24–85 | 33F | Melasma | Tropical fern or polypodium leucotomos | Supplement | Tropical fern supplement (240 mg) three times a day | Placebo | 12 W | melanin and MASI score | Despite the improvement of melanin and MASI score in both groups, there was no significant difference between the two groups | No side effects |
| Lima et al. (2020) [35] | Clinical trial | 44 | 39 ± 7 years | 44F | Melasma | Pine bark or maritime pine bark (pcnogenol) | Supplement | Pycnogenol supplement 75 mg twice daily | Placebo | 60 Days | Criteria of mMASI score and quality of life in patients with melasma | According to the two criteria of mMASI score and quality of life, it seems that pyconogenol significantly improves these two factors | No side effects |
| Neda Bavarsad et al. (2020) [36] | Clinical trial | 22 | Average 33.5 ± 7.8 in placebo group and 34.7 ± 10.2 in the molten group | 22F | Melasma | Tomato | Cream | Combination of 0.05% lycopene extracted from tomato and wheat bran 3.45% twice a day | Placebo | 3 Months | MASI score | The patients in the control group and the intervention group were not different in the MASI score 1 month after discontinuation | No side effects |
| Adilson Costa et al. (2010) [37] | Clinical trial | 56 | 18–60 | 56F | Epidermal melasma and mixed melasma | Indian gooseberry or emblica | Topical | Topical use of Indian gooseberry and licorice 7% twice a day | 2% hydroquinone cream | 60 Days | Pigmentation rate | No significant difference between the two groups in terms of disease improvement | No side effects |
| Hayra D Avianggi et al. (2022) [38] | Clinical trial | 62 | 35‐55 | 62F | Melasma | Tomato | Oral | Oral tomato extract supplement (lycopene 30 mg) plus topical sunscreen and hydroquinone 4%cream | All subjects applied topical sunscreen and hydroquinone 4%cream | 12 W | Superoxide dismutase (SOD), and MASI score | SOD level was higher in the treatment group and MASI score was also significantly decreased | No side effects |
| Penpun Wattanakrai et al. (2022) [39] | Clinical trial | 25 | Epidermal or mixed‐type | Milk thistle | Topical | Silymarin cream on one side | Hydroquinone on the contralateral side | 3 months | Colorimeter by relative lightness index (RL*I), mMASI score, and patient self‐assessment | mMASI scores decreased after both treatments but only significant on hydroquinone side (17.97% reduction (p = 0.02) vs. 7.11% (p = 0.32) on the silymarin side) no significant difference of the RL*I and mMASI score between the 2 treatments, patient satisfaction was quite similar | |||
| Shamsi et al. (2023) [40] | Clinical trial | 55 | 20–55 | 49F, 6M | Epidermal | Lentil, bitter almond, and fig | Topical | Tila‐e‐Kalf (fine powder of lentil ( Lens culinaris ) and bitter almond (Prunus amygdalus var.amara) in equal proportion then mixed with the decoction of fig ( Ficus carica ) in to make a homogenous paste) once daily | Hydroquinone 4% cream | 8 W | MASI score and, DLQI (Dermatology Life Quality Index), and PGA (Physician Global Assessment) and colored photographs | Similar improvement was noticed in all parameters | One patient had mild itching |
| Javedan et al. (2021) [41] | Clinical trial | 49 | Mean age of 32.18 ± 8.69 | 40F, 9M | Melasma | Dorema ammoniacum | Topical | 6% D. ammoniacum gum combined with oserin in 10% ratio | Placebo | 30 days | Mean melasma severity index (MMASI) score | Mean Melasma severity index (MMASI) score in the treatment group was significantly lower than before treatment (decreased from 86.98 ± 69.48 to 31.03 ± 32.62 (p < 0.05).) | No side effects |
| Bakhtyari et al. (2024) [42] | Clinical trial | 110 | > 40 | 110F | Female participants who were aged 15 years or older | Polyherbal Syrup Containing Lemon Balm, Damask Rose, and Fennel | Oral | Polyherbal Syrup Containing Lemon Balm, Damask Rose, and Fennel | Placebo | 12w | MELASQOL, MASI score, Mexameter MX18 to measure Melanin and Erythema | Significant reduction in MASI score, melanin, pigmentation, MelasQOL | No obvious side effects |
| Kheirieh et al. (2024) [43] | Clinical trial | 30 | Mean age of 2.73 ± 6.98 | 30F | Female patients diagnosed with epidermal facial melasma | T. chebula 5% cream | Topical | T. chebula 5% cream | Hydroquinone 2% cream | 12 W | mMASI score | mMASI score was significantly reduced in T. chebula group 4, 8, and 12 weeks after initiating the study. | No side effects |
Abbreviations: MASI, Melasma Area Severity Index; mMASI, modified Melasma Area Severity Index.
3.1. Rhubarb
Zhang Hui and colleagues conducted a study on 31 melasma patients. The patients were divided into two groups: one group received a placebo, while the other group received rhubarb in liquid form. Patient satisfaction and improvement of melasma were evaluated in follow‐ups conducted at 4, 8, and 12 weeks. The patients took the drug twice a day for a duration of 8 weeks. The study found that patient satisfaction with rhubarb was 79.31%, whereas with the placebo, it was only 24.14%. The study also evaluated improvements in pigmentation and melanin index between the two groups. However, the results showed no significant difference between the placebo and rhubarb in terms of improving melasma spots. Interestingly, the melanin index increased again in the 8th week, despite a decrease in the 4th week. After completing the study, the melanin index was measured at 12 weeks, the results of which indicated a worsening of the melanin index (however, the melanin index decreased compared to the first day of the study). The deterioration of patients can be due to stopping sunscreen consumption after the end of the study. No significant complications were observed in either group [44].
Several studies have proven the anti‐inflammatory, anti‐scarring, and antioxidant effects of rhubarb. The plant's anti‐inflammatory and antioxidant properties seem to have a positive impact on sunlight‐induced melasma, especially at higher concentrations [44, 45]. However, further studies with larger sample sizes and the determination of the active ingredient of this plant are necessary to investigate its effect on melasma‐induced spots.
3.2. Chickpea
According to Persian medicine sources, chickpea is recognized as a skin lightening plant that can reduce skin lesions caused by melasma [46, 47]. The mechanism of action of this plant is inhibition of the tyrosinase enzyme and free radicals [29]. In a study, the effectiveness of a combination of chickpea and melon seed compositions was compared with the effect of 4% hydroquinone. The study evaluated the impact of these plants on melasma severity over a period of 12 weeks. The results demonstrated that this combination of drugs can significantly improve melasma‐induced spots without causing any serious side effects. Both groups showed significant improvement after 12 weeks [26].
3.3. Melon Seed
A recent study looked at how melon seed affects melasma and discovered that the anti‐tyrosinase properties of the seeds, when mixed with chickpeas (10%), may effectively improve spots caused by melasma [26]. However, research on this plant's ability to reduce pigmentation remains limited.
3.4. Sorrel
A study comparing the effects of sorrel and hydroquinone revealed that using a 3% sorrel cream for 12 weeks can significantly clarify and reduce the color of melasma spots. The study utilized Mexameter and the MASI (Melasma Area Severity Index) score to compare the sorrel and hydroquinone groups. From weeks 2 to 6, the hydroquinone group showed considerable improvement, surpassing the sorrel group. However, in the week 8 evaluation, the sorrel group exhibited a higher decrease in the MASI score compared to the hydroquinone group [27]. Nevertheless, there is a scarcity of studies on the effects of sorrel, and the exact mechanism of its impact remains unclear. It is believed that sorrel reduces pigmentation through its anti‐inflammatory activity and inhibition of tyrosinase.
3.5. Aloe vera
Numerous studies have proven the anti‐inflammatory, anti‐scar, lightening, and free radical‐reducing properties of Aloe vera [48]. However, when compared to phenylalanine 2%, the effect of this plant did not show significant results [28]. Additionally, evidence suggests that the using gel encapsulated with liposomes is more effective than using the gel alone [49]. The plant's impact on reducing pigmentation and its precise mechanism of action require further research.
3.6. Parsley
In traditional Persian medicine, parsley has long been recognized for its skin lightening and anti‐stain properties [50]. Several clinical trials have also confirmed the herb's ability to lighten the skin [51, 52]. It appears that parsley is effective in treating melasma by exerting an anti‐pigmentation effect. The study conducted by Shahla Khosravan et al. showed that this plant affects melasma‐induced spots; however, its effect is equal to hydroquinone 4% [50].
3.7. Licorice
Licorice is one of the most widely used plants in traditional medicine and is complementary to the treatment of skin diseases [24]. Numerous studies have confirmed its lightening and antioxidant effects. However, two specific studies found that the plant's effectiveness was higher than a placebo but lower than a hydroquinone 4% cream [24, 25, 29]. Another significant study revealed that when topical treatment of licorice is combined with 5% ascorbic acid, the recovery rate of patients significantly increases [31].
3.8. Tomatoes
Ancient texts have mentioned tomatoes as a natural remedy for lightening the face and reducing dark spots. Recent clinical trials have shown that patients who took tomato supplements alongside standard melasma treatment (hydroquinone 4%) experienced a greater improvement in their condition [30].
Another study found that using this plant in conjunction with rice bran also improved melasma‐induced blur. The reduction of the MASI score in the group that used the topical combination of tomato lycopene and rice bran was significantly higher than in the placebo group. Moreover, the reduction in size of the melasma lesions was significantly greater in the patients in the intervention group in comparison with the patients in the other group of the study. However, 1 month after discontinuation of this topical compound, the severity of the disease did not show any difference from the control group [36]. The level of superoxide dismutase (SOD) went up in a more recent study by Avianggi et al. when tomato lycopene extract supplements were added to sunscreen and hydroquinone 4% cream. This addition further improved the MASI scores of patients in the treatment group, showing a significant difference from the control group that only received sunscreen and hydroquinone 4% cream [38].
3.9. Tropical Fern
While there have been few studies on the effect of tropical fern on melasma lesions, one clinically conducted study examined the quality of life and severity of melasma in patients who received oral supplementation of tropical fern alongside standard treatment. The results of this study also indicated the effectiveness of tropical ferns in improving melasma symptoms. A comparison of the results of treatment in the follow‐up of patients showed that the group that used tropical fern supplements responded more quickly to treatment. However, in this study, the mechanism of action and active substance of this plant were not determined [32].
Moreover, 33 patients participated in another trial study, where 17 patients received a placebo three times a day and 17 patients received an equatorial fern supplement (240 mg) three times a day. The authors evaluated melanin, MASI score, and the quality of life index after 12 weeks. At the end of the 12th week, both groups showed significant improvements in the melanin standard index (placebo group 13.8% and intervention group 28.8%); however, there was no statistically significant difference between the two groups. Similarly, the MASI score in both groups decreased during the 12 weeks, but there was no difference between the two groups. Therefore, according to the results of this study, the effect of tropical fern on melasma is similar to that of a placebo [34].
3.10. Olive
A study has investigated the effects of both topical and edible olive oil on melasma. The study involved 42 women with melasma, divided into three groups. The first group received oral and topical placebos; the second group received an oral placebo and topical olive oil; and the third group received oral olive oil and topical placebos. We measured the melanin index and mMASI (modified Melasma Area Severity Index) score in all groups at the start of the study, and again after 60 days. The results showed that although the group treated with edible olive oil showed greater improvement, there was no significant difference between the oral and topical application of olive oil and the placebos. However, using edible olive oil for 60 days did significantly reduce the melanin index and mMASI score [33].
3.11. French Sea Pine Bark
In a study, pycnogenol extracted from the pine bark was orally evaluated in patients with melasma. The study included the standard three‐drug topical treatment for melasma patients and sunscreen, with the addition of pycnogenol in the intervention group. The results showed that this supplement effectively improved the quality of life for melasma patients and had a positive impact on the severity of melasma. It seems that the antioxidant properties in the extract of this plant have caused this efficacy [35].
3.12. Indian Gooseberry
A trial study also studied the effect of this plant in combination with licorice on blurs caused by melasma disease. 50 patients participated in this study, with 23 in the hydroquinone 2% group and 27 in the 7% Indian gooseberry and licorice intervention group. The overall results of this study showed that the combination of this plant with licorice compared to 2% hydroquinone was not significantly different in the treatment of melasma patients [37].
3.13. Milk Thistle
The silymarin extract from milk thistle was studied in a split‐side trial. 25 patients who had epidermal or mixed‐type melasma were selected. In this regard, 1.4% silymarin cream was applied on one side of the patient's face and 2% hydroquinone on the contralateral side for 3 months. mMASI scores decreased on both sides but were only statistically significant on the hydroquinone side, which caused a 17.97% reduction vs. only 7.11% on the silymarin side. No statistical difference in mMASI was found between the two groups [39].
3.14. Lentil, Bitter Almond, and Fig (Tila‐e‐Kalf)
Tila‐e‐Kalf is an Unani pharmacopoeial formulation used in a clinical trial for treating melasma. This remedy is made from a mixture of lentil and bitter almond powder, which is then added to the decoction of fig to form a homogenous paste. The control group received 4% hydroquinone. Both treatment and control groups were advised to apply sunscreen twice a day. This study revealed that Tila‐e‐Kalf has the same effect as hydroquinone. Only one patient treated with Tila‐e‐Kalf experienced mild itching, whereas the patients treated with hydroquinone cream reported more side effects [40].
3.15. Dorema ammoniacum
Dorema ammoniacum is an herb native to Iran with anti‐inflammatory effects. In the study conducted by Javedan et al., 49 patients were separated into control and drug groups; they received placebo and the drug, respectively, twice a day for 30 days. Javedan et al. administered the remedy in the form of a 6% topical gum. The results of this study demonstrated that Dorema ammoniacum was significantly more effective in treating melasma in comparison with placebo [41].
3.16. Multi‐Herbal Syrup Containing Lemon Balm, Damask Rose, and Fenne
Lemon balm is a natural remedy with antibacterial and anti‐inflammatory effects that is effective in skin rejuvenation [53, 54]. Damask rose is also effective in skin rejuvenation, with effects on hydration, improvement of stretch marks and wrinkles, acne control, and pigmentation reduction [55, 56]. Fennel possesses anti‐inflammatory and anti‐melanogenesis properties, making it an effective treatment for both digestive issues and skin diseases [57, 58, 59]. A randomized, triple‐blind, placebo‐controlled clinical trial was done with 110 patients (12 weeks) to see how well this multi‐herbal syrup treated melisma. The intervention group had 55 and the placebo group 55. Parameters including melanin, lightness, pigmentation, and the Melasma Quality of Life (MELASQOL) were significantly different in comparison to placebo. Therefore, this multi‐herbal syrup is an effective treatment for melisma [42].
3.17. Terminalia chebula Retz
Terminalia chebula Retz. ( T. chebula ), native to India and Southeast Asia, is most important and is used orally and topically in traditional medicine. T. chebula is a beneficial choice for treating melisma due to its antioxidant, anti‐inflammatory, and tyrosinase enzyme inhibitory activities. In a randomized, controlled, triple‐blind clinical trial, one group received T. chebula 5% cream and the other hydroquinone 2% cream at bedtime for 12 weeks. T. chebula groups significantly reduced their mMASI score 4, 8, and 12 weeks after initiating the study. The T. chebula group significantly reduced skin irritation compared to the hydroquinone group [43].
4. Discussion
Even though there are various therapies available for melasma, none of them guarantee a satisfactory result, and the management of this condition remains a challenge. Humans have used herbal medicine for centuries, and it may hold the key to many of modern medicine's mysteries. We aimed to review the articles that examined the efficacy and safety of various herbal drugs in the treatment of melasma.
With this goal in mind, a total of 21 articles were reviewed and evaluated by type of plant. No patient had any severe reactions to the herbs, and only seven patients had mild reactions to some of the herbal medications used (parsley, licorice, rhubarb, and Tila‐e‐Kalf), which could argue for the safety of these herbs [24, 37]. As observed, it seems that parsley, licorice, sorrel, chickpeas, tropical fern, tomato, pine bark (pycnogenol), Dorema ammoniacum , melon seed, Tila‐e‐Kalf (lentil, bitter almond, and fig), T. chebula , and a polyherbal syrup containing Lemon Balm, Damask Rose, and Fennel had effects to some extent on melasma‐induced stains [24, 27, 33, 41, 50].
Licorice caused significantly better results than placebo but was less effective than hydroquinone cream [24, 25]. Researchers also discovered that combining 4% licorice with 5% ascorbic acid led to a more significant improvement compared to using 4% licorice alone [31]. Another study compared a mixture of licorice and gooseberry with 2% hydroquinone cream and found no significant difference between them in treatment of melasma [37]. Studies have shown that licorice with a melanin dispersibility mechanism can lead to depigmentation. In the study of Yokota and his colleagues and Matoorianpour et al., it has also been shown that licorice reduces melanocyte activity and melanin production due to glabridin (a flavonoid compound), which reduces pigmentation in patients. It seems that this plant can be effective in improving this disease by reducing melanocyte production [60]. Researchers have reported using licorice to treat skin pigmentation because of its tyrosinase inhibitory activity. Therefore, compounds that function as tyrosinase inhibitors have a significant impact on cosmetic items as agents that lighten the skin and in the management of certain dermatological conditions. Furthermore, flavonoids constitute the predominant category of natural phenolic compounds that function as inhibitors of tyrosinase. Licorice extracts and three main flavonoids—licochalcone A, glabridin, and dehydroglyasperin C—are the compounds that have been studied the most in dermatology for their skin‐whitening and anti‐aging effects [61, 62, 63, 64].
Evidence showed that a mixture of chickpeas and melon seeds could be an acceptable herbal regime for the treatment of patients with melasma. In this context, the Iranian population commonly uses chickpea as a drug and food, prompting several studies to investigate its therapeutic effects [26, 65, 66]. Evidence demonstrated that chickpeas have anti‐tyrosinase and antioxidant activities, which could potentially have anti‐hyperpigmentation and skin‐whitening effects [67].
Sorrel was compared to hydroquinone cream; the standard treatment showed better improvements from the 2nd week until the 6th, but after 8 weeks of treatment, the sorrel group showed significantly better results. The sorrel plant reduces melanin production with a tyrosinase inhibition mechanism and thus effectively improves hyperpigmentation disorders such as melasma [27, 60]. In addition, parsley had similar results to hydroquinone cream [50]. Tomato supplements (lycopene extract) also caused a significant improvement in patients' disease compared to placebo. It was also efficient at increasing the benefits of routine treatment with sunscreen and 4% hydroquinone by increasing the levels of SOD [30, 38].
Evidence revealed that some plants, such as tomatoes, sorrels, and parsley, have antioxidant properties and could improve the severity of melasma disease due to the reduction of free radicals [36, 68]. Especially in patients with melasma, sunlight exposure caused more severe symptoms. These plants could also have preventive properties for these susceptible individuals [30, 36]. Despite the significant effects of some of these plants on melasma, even compared to the current standard of treatment drugs, there are few studies in this field, and only a few clinical trials have been conducted on these plants and their effects on skin darkening caused by melasma.
A combination of 0.05% lycopene extracted from tomato and 3.45% wheat bran topical use showed improvements in pigmentation while using the treatment, but 1 month after discontinuation of the drug, no significant difference was seen between treated patients and those receiving placebo [36]. Tropical fern supplements showed mixed results compared to placebo; one study found significance compared to placebo, and the other found no difference [32, 34]. The pine bark pycnogenol supplement helped improve the outcome in patients receiving the standard three‐drug treatment, probably due to its antioxidant properties [35].
Lentil, bitter almond, and fig mixture (Tila‐e‐Kalf) had the same effect as 4% hydroquinone cream with fewer side effects [29]. Dorema ammoniacum was also shown to be significantly better than placebo, but the conclusion cannot be relied upon due to the randomization issue in the study [41]. Rhubarb, aloe vera , silymarin extract from milk thistle, and olive showed no significant improvement in patient outcomes [28, 33, 39]. Although edible olive oil use for 60 days did reduce the melanin index and mMASI score, it had no significant difference from the placebo and topical olive oil groups during 90 days of administration [33]. However, the authors recommend designing similar studies on these herbal remedies for the treatment of melasma and other skin hyperpigmentation conditions, using different doses, shapes, formulations, and concentrations of the cosmetic products or medicine.
Traditional Persian medicine texts like Bu‐Ali Sina Law, Al‐Hawi Razi, Reservoir al‐Adouyeh, and the Book of Akbari Medicine list several plants with anti‐pigmentation properties. This text suggests saffron as a plant that reduces facial skin stains and mentions it as a treatment for melasma [69]. The active ingredients of the saffron plant are crocetin and carotenoids, which prevent the production of free radicals in the skin [70]. Researchers have also mentioned fumaria parviflora and leek plants as skin protectors against ultraviolet radiation and sunlight, thanks to their phenolic and ascorbic acid compounds. Researchers have also reported their effectiveness in treating melasma by reducing stain and lightening the skin in these patients [9]. Other plants, such as fenugreek, grapes, figs, and celery, were mentioned in Iranian medicine texts. They have the ability to lessen the darkening resulting from melasma and shield the skin from intensifying these stains [69]. It is also stated that the compounds affecting melasma in these plants include phenolic, carotenoid, crastin, ascorbic acid, tannins, tyrosinase inhibitors, and anti‐inflammatory compounds [37].
Previous research has not clearly stated the mechanisms of action of some herbal remedies presented in this scoping review study. However, it looks like the tyrosinase inhibitors, retinoid, and anti‐inflammatory compounds in these plants are crucial in reducing pigmentation in these patients [48, 71, 72, 73, 74]. In addition, phytochemicals may mitigate the detrimental effects of UV radiation on human skin. Phenolic compounds constitute the most significant category of phytochemicals that can function as sunscreen agents. In this regard, evidence suggests that apigenin and chlorogenic acid, two phenolic compounds, are the most effective UVB and UVA filters for treating skin hyperpigmentation and preventing its onset or exacerbation [75, 76]. Several studies have also shown that secondary metabolites found in plants can change the way melanocyte cells communicate during the melanogenesis process. Regarding this, numerous studies have focused on the regulation of the MC1R, c‐KIT, WNT, and ETBR pathways, which are essential in modulating skin pigmentation and melanocyte production [75, 77, 78].
This study was subject to several limitations. First, the authors focused on the published articles for inclusion in the study, so the gray literature was not investigated in this study. Second, there were few studies on the treatment of patients with melasma, so because of the methodological heterogeneity of the studies and the low number of studies, conducting a meta‐analysis was not applicable. Then, the risk of bias assessment of the included articles was not considered in this study, so the authors recommend considering this issue in future studies. Next, a network meta‐analysis to compare the efficacy of different herbal medications in treating patients with melasma was not the goal of this study; the authors suggest this issue in further studies. Finally, the phytochemical components and mechanism of action of these herbal remedies in threating melasma and skin hyperpigmentation were not definitely discovered. Therefore, we recommend further studies to unravel these properties.
5. Conclusion
Despite the antioxidant, anti‐tyrosinase, and illuminating properties of many medicinal plants and the several recommendations of traditional Persian medicine sources on the effect of these plants, few studies have investigated the effect of these plants on melasma‐induced skin spots. In addition, the existing evidence about the effects of these plants is still inadequate, and further studies with larger sample sizes are needed to confirm the effects of these plants.
Author Contributions
M.M.P. and N.S. designed the study. M.M.P., N.Y., A.M., M.H., and R.J. collected the data. M.M.P., R.J., M.H., N.Y., and A.M. drafted the manuscript. M.M.P., N.S., and M.H. finalized the manuscript. All authors reviewed the manuscript and approved the final version. They take full responsibility for the content and writing of this article.
Ethics Statement
The protocol of this study was approved by the Ethics Committee of Shiraz University of Medical Sciences (Ethics code: IR.SUMS.MED.REC.1399.597).
Conflicts of Interest
The authors declare no conflicts of interest.
Acknowledgments
The authors would like to thank the Vice Chancellor of Research, Shiraz University of Sciences, Shiraz, Iran, for supporting this project (Proposal No. 22633).
Funding: This study was financially supported by the Vice of Research of Shiraz University of Medical Sciences for financial support of this study (Grant No.22633).
Contributor Information
Mohammad Mahdi Parvizi, Email: mmparvizi@gmail.com.
Nasrin Saki, Email: nasrinsa85@yahoo.com.
Data Availability Statement
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restriction.
References
- 1. Majid I. and Aleem S., “Melasma: Update on Epidemiology, Clinical Presentation, Assessment, and Scoring,” Journal of Skin and Stem Cell 8, no. 4 (2021): e120283, 10.5812/jssc.120283. [DOI] [Google Scholar]
- 2. Ogbechie‐Godec O. A. and Elbuluk N., “Melasma: An Up‐To‐Date Comprehensive Review,” Dermatology and Therapy 7 (2017): 305–318. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Legarda‐Montinola F., “Classification and Clinical Presentations of Melasma in Brown Skin,” Melasma and Vitiligo in Brown Skin (2017): 33–40, 10.1007/978-81-322-3664-1_5. [DOI] [Google Scholar]
- 4. Sarkar R., Ailawadi P., and Garg S., “Melasma in Men: A Review of Clinical, Etiological, and Management Issues,” Journal of Clinical and Aesthetic Dermatology 11, no. 2 (2018): 53–59. [PMC free article] [PubMed] [Google Scholar]
- 5. Sarkar R., Arora P., Garg V. K., Sonthalia S., and Gokhale N., “Melasma update,” Indian Dermatology Online Journal 5, no. 4 (2014): 426. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Miot L. D. B., Miot H. A., Silva M. G., and Marques M. E. A., “Physiopathology of Melasma,” Anais Brasileiros de Dermatologia 84 (2009): 623–635. [DOI] [PubMed] [Google Scholar]
- 7. Achar A. and Rathi S. K., “Melasma: A Clinico‐Epidemiological Study of 312 Cases,” Indian Journal of Dermatology 56, no. 4 (2011): 380–382. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Jadotte Y. T. and Schwartz R. A., “Melasma: Insights and Perspectives,” Acta Dermatovenerologica Croatica 18, no. 2 (2010): 124–129. [PubMed] [Google Scholar]
- 9. Handel A., Lima P., Tonolli V., Miot L., and Miot H. A., “Risk Factors for Facial Melasma in Women: A Case–Control Study,” British Journal of Dermatology 171, no. 3 (2014): 588–594. [DOI] [PubMed] [Google Scholar]
- 10. Cestari T., Peruzzo J., and Giongo N., “Definition, Incidence, and Etiology of Melasma in Brown Skin,” Melasma and Vitiligo in Brown Skin (2017): 13–19, 10.1007/978-81-322-3664-1_3. [DOI] [Google Scholar]
- 11. Passeron T. and Picardo M., “Melasma, a Photoaging Disorder,” Pigment Cell & Melanoma Research 31, no. 4 (2018): 461–465. [DOI] [PubMed] [Google Scholar]
- 12. Gopichandani K., Arora P., Garga U., Bhardwaj M., Sharma N., and Gautam R. K., “Hormonal Profile of Melasma in Indian Females,” Pigment International 2, no. 2 (2015): 85–90. [Google Scholar]
- 13. Passeron T., “Melasma Pathogenesis and Influencing Factors–an Overview of the Latest Research,” Journal of the European Academy of Dermatology and Venereology 27 (2013): 5–6. [DOI] [PubMed] [Google Scholar]
- 14. Kheradmand M., Afshari M., Damiani G., Abediankenari S., and Moosazadeh M., “Melasma and Thyroid Disorders: A Systematic Review and Meta‐Analysis,” International Journal of Dermatology 58, no. 11 (2019): 1231–1238. [DOI] [PubMed] [Google Scholar]
- 15. Hexsel D., Lacerda D. A., Cavalcante A. S., et al., “Epidemiology of Melasma in B Razilian Patients: A Multicenter Study,” International Journal of Dermatology 53, no. 4 (2014): 440–444. [DOI] [PubMed] [Google Scholar]
- 16. Ardigo M., Cameli N., Berardesca E., and Gonzalez S., “Characterization and Evaluation of Pigment Distribution and Response to Therapy in Melasma Using In Vivo Reflectance Confocal Microscopy: A Preliminary Study,” Journal of the European Academy of Dermatology and Venereology 24, no. 11 (2010): 1296–1303. [DOI] [PubMed] [Google Scholar]
- 17. Rodrigues M. and Pandya A. G., “Melasma: Clinical Diagnosis and Management Options,” Australasian Journal of Dermatology 56, no. 3 (2015): 151–163. [DOI] [PubMed] [Google Scholar]
- 18. McKesey J., Tovar‐Garza A., and Pandya A. G., “Melasma Treatment: An Evidence‐Based Review,” American Journal of Clinical Dermatology 21 (2020): 173–225. [DOI] [PubMed] [Google Scholar]
- 19. Sehgal V. N., Verma P., Srivastava G., Aggarwal A. K., and Verma S., “Melasma: Treatment Strategy,” Journal of Cosmetic and Laser Therapy 13, no. 6 (2011): 265–279. [DOI] [PubMed] [Google Scholar]
- 20. Trivedi M., Yang F., and Cho B., “A Review of Laser and Light Therapy in Melasma,” International Journal of Women's Dermatology 3, no. 1 (2017): 11–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Arora P., Sarkar R., Garg V. K., and Arya L., “Lasers for Treatment of Melasma and Post‐Inflammatory Hyperpigmentation,” Journal of Cutaneous and Aesthetic Surgery 5, no. 2 (2012): 93–103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Zhang Q., Tu Y., Gu H., et al., “A Cream of Herbal Mixture to Improve Melasma,” Journal of Cosmetic Dermatology 18, no. 6 (2019): 1721–1728. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Parvizi M. M., Fatehi N., Jaladat A. M., Gholampour Z., Shahriarirad R., and Erfani A., “Epidemiological Factors in Patients With Dermatologic Conditions Referring to the Clinic of Traditional Persian Medicine: A Cross‐Sectional Study,” International Journal of Clinical Practice 75, no. 11 (2021): e14788. [DOI] [PubMed] [Google Scholar]
- 24. Pour H. M., Pour M. R., Delfan B., and Tarrahi M. J., “Effect of Licorice Extract in the Treatment of Melasma,” Scientific Magazine Yafte 11, no. 5 (2010): 15–23. [Google Scholar]
- 25. Amer M. and Metwalli M., “Topical Liquiritin Improves Melasma,” International Journal of Dermatology 39, no. 4 (2000): 299–301. [DOI] [PubMed] [Google Scholar]
- 26. Mahjour M., Banihashemi M., Rakhshandeh H., Vakili V., Khoushabi A., and Kakhki M. T., “A Triple‐Blind, Randomized Trial of a Traditional Compound as Compared to 4% Hydroquinone in Melasma,” Journal of Herbal Medicine 19 (2020): 100308. [Google Scholar]
- 27. Mendoza C. G., Singzon I. A., and Handog E. B., “A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial on the Efficacy and Safety of 3% R Umex Occidentalis Cream Versus 4% Hydroquinone Cream in the Treatment of Melasma Among F Ilipinos,” International Journal of Dermatology 53, no. 11 (2014): 1412–1416. [DOI] [PubMed] [Google Scholar]
- 28. Naqvi F., Imran I., Faraz A. A. K., Tabussam T., and Sikandar S., “A Double Blind Study to Compare the Efficacy of Aloe vera Gel and Undecylenoyl Phenylalanine 2% for Treatment of Melisma,” Professional Medical Journal 27, no. 8 (2020): 1770–1776. [Google Scholar]
- 29. Shamsi Meymandi S., Mohammadzadeh Shanehsaz S., and Ansari M., “Efficacy of Licorice Extract in the Treatment of Melasma: A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial,” Journal of Dermatology and Cosmetic 7, no. 1 (2016): 1–9. [Google Scholar]
- 30. Afriliana L., Budipradigda L., and Djamiatun K., “The Effect of Tomato Extract Supplementation to Interleukin‐17 Serum Level in Women With Melasma,” International Journal of Pharmaceutical Research 12, no. 4 (2020): 31838. [Google Scholar]
- 31. Akram S., Sattar F., Tahir R., and Mujtaba G., “Efficacy of Topical 4% Liquiritin Compared With Topical 4% Liquiritin Mixed in 5% Ascorbic Acid in the Treatment of Melasma,” Journal of Pakistan Association of Dermatologists 23, no. 2 (2013): 149–152. [Google Scholar]
- 32. Goh C.‐L., Chuah S. Y., Tien S., Thng G., Vitale M. A., and Delgado‐Rubin A., “Double‐Blind, Placebo‐Controlled Trial to Evaluate the Effectiveness of Polypodium Leucotomos Extract in the Treatment of Melasma in Asian Skin: A Pilot Study,” Journal of Clinical and Aesthetic Dermatology 11, no. 3 (2018): 14. [PMC free article] [PubMed] [Google Scholar]
- 33. Bagatin J., Berardo Gonçalves Ma P., and Bagatin E., “A Pilot Clinical Study to Evaluate the Effectiveness of Olive Extract Containing Hydroxytyrosol for Oral and Topical Treatment of Melasma,” Biomedical and Biopharmaceutical Research 17, no. 1 (2020): 1–15. [Google Scholar]
- 34. Ahmed A. M., Lopez I., Perese F., et al., “A Randomized, Double‐Blinded, Placebo‐Controlled Trial of Oral Polypodium Leucotomos Extract as an Adjunct to Sunscreen in the Treatment of Melasma,” JAMA Dermatology 149, no. 8 (2013): 981–983. [DOI] [PubMed] [Google Scholar]
- 35. Lima P., Dias J., Esposito A., Miot L., and Miot H., “French Maritime Pine Bark Extract (Pycnogenol) in Association With Triple Combination Cream for the Treatment of Facial Melasma in Women: A Double‐Blind, Randomized, Placebo‐Controlled Trial,” Journal of the European Academy of Dermatology and Venereology 35, no. 2 (2021): 502–508. [DOI] [PubMed] [Google Scholar]
- 36. Bavarsad N., Mapar M. A., Safaezadeh M., and Latifi S. M., “A Double‐Blind, Placebo‐Controlled Randomized Trial of Skin‐Lightening Cream Containing Lycopene and Wheat Bran Extract on Melasma,” Journal of Cosmetic Dermatology 20, no. 6 (2021): 1795–1800. [DOI] [PubMed] [Google Scholar]
- 37. Costa A., Moisés T. A., Cordero T., Alves C. R. T., and Marmirori J., “Association of Emblica, Licorice and Belides as an Alternative to Hydroquinone in the Clinical Treatment of Melasma,” Anais Brasileiros de Dermatologia 85 (2010): 613–620. [DOI] [PubMed] [Google Scholar]
- 38. Avianggi H. D., Indar R., Adriani D., et al., “The Effectiveness of Tomato Extract on Superoxide Dismutase (SOD) and Severity Degree of Patients With Melasma,” Italian Journal of Dermatology and Venereology 157, no. 3 (2022): 262–269. [DOI] [PubMed] [Google Scholar]
- 39. Wattanakrai P. and Nimmannitya K., “A Randomized, Double‐Blind, Split‐Face Study of Topical Silymarin vs 2% Hydroquinone Cream in Melasmas,” Journal of Drugs in Dermatology: JDD 21, no. 12 (2022): 1304–1310. [DOI] [PubMed] [Google Scholar]
- 40. Shamsi Y., Nikhat S., Manjhi M., Akhtar M. W., and Ahmad S., “Clinical Evaluation of a Topical Unani Pharmacopoeial Formulation Tila‐e‐Kalf in the Management of Melasma (Kalf): A Randomized Controlled Clinical Trial,” Avicenna Journal of Phytomedicine 13, no. 3 (2023): 225–264. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Javedan K., Hydarpur F., Mohammadi Pour P., et al., “The Formulation and Efficacy of Topical Dorema ammoniacum in Treating Melasma: A Randomized Double‐Blind, Placebo‐Controlled Trial,” Journal of Complementary and Integrative Medicine 19, no. 3 (2021): 743–751. [DOI] [PubMed] [Google Scholar]
- 42. Bakhtyari L., Shirbeigi L., Tabarrai M., Rahimi R., and Ayatollahi A., “Efficacy of a Polyherbal Syrup Containing Lemon Balm, Damask Rose, and Fennel to Treat Melasma: A Randomized, Triple‐Blind, Controlled Clinical Trial,” Jundishapur Journal of Natural Pharmaceutical Products 18, no. 3 (2023): e138392. [Google Scholar]
- 43. Kheirieh A. E., Sharififar F., Ansari Dogaheh M., Dabaghzadeh F., Shamsi Meymandi S., and Bakhshoudeh B., “Evaluating the Efficacy of Terminalia chebula Retz. 5% Cream Compared to Hydroquinone 2% Cream in the Treatment of Melasma,” Avicenna Journal of Phytomedicine 14, no. 5 (2024): 527–536. [Google Scholar]
- 44. Hui Z., “A Study Of Efficacy Result Between Topical Herbal Rhubarb Liquid and Liquid Base for the Treatment of Melasma in Thai People”.
- 45. Zhou Y.‐X., Xia W., Yue W., Peng C., Rahman K., and Zhang H., “Rhein: A Review of Pharmacological Activities,” Evidence‐based Complementary and Alternative Medicine 2015 (2015): 1–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Aghili A., Rahimi R., and Shams‐Ardekani M., Makhzan ul‐Advia (Tehran: University of Medical Sciences, 2009). [Google Scholar]
- 47. Arzani M., Teb‐e‐Akbari [Akbari's medicine] (Research Institute for Islamic and Complimentary Medicine: Tehran, Iran, 2008), 250–254. [Google Scholar]
- 48. Sarkar R., Arora P., and Garg K. V., “Cosmeceuticals for Hyperpigmentation: What Is Available?,” Journal of Cutaneous and Aesthetic Surgery 6, no. 1 (2013): 4–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Ghafarzadeh M. and Eatemadi A., “Clinical Efficacy of Liposome‐Encapsulated Aloe vera on Melasma Treatment During Pregnancy,” Journal of Cosmetic and Laser Therapy 19, no. 3 (2017): 181–187. [DOI] [PubMed] [Google Scholar]
- 50. Khosravan S., Alami A., Mohammadzadeh‐Moghadam H., and Ramezani V., “The Effect of Topical Use of Petroselinum crispum (Parsley) Versus That of Hydroquinone Cream on Reduction of Epidermal Melasma: A Randomized Clinical Trial,” Holistic Nursing Practice 31, no. 1 (2017): 16–20. [DOI] [PubMed] [Google Scholar]
- 51. Austin E., Nguyen J. K., and Jagdeo J., “Topical Treatments for Melasma: A Systematic Review of Randomized Controlled Trials,” Journal of Drugs in Dermatology: JDD 18, no. 11 (2019): S1545961619P1156X. [PubMed] [Google Scholar]
- 52. Adhikari A., Devkota H., Takano A., et al., “Screening of Nepalese Crude Drugs Traditionally Used to Treat Hyperpigmentation: In Vitro Tyrosinase Inhibition,” International Journal of Cosmetic Science 30, no. 5 (2008): 353–360. [DOI] [PubMed] [Google Scholar]
- 53. Pérez‐Sánchez A., Barrajón‐Catalán E., Herranz‐López M., Castillo J., and Micol V., “Lemon Balm Extract (Melissa officinalis, L.) Promotes Melanogenesis and Prevents UVB‐Induced Oxidative Stress and DNA Damage in a Skin Cell Model,” Journal of Dermatological Science 84, no. 2 (2016): 169–177. [DOI] [PubMed] [Google Scholar]
- 54. Ullah M. A. and Hassan A., “Medicinal Benefits of Lemon Balm ( Melissa officinalis ) for Human Health,” World Journal of Chemical and Pharmaceutical Sciences 1, no. 1 (2022): 28–33. [Google Scholar]
- 55. Pasalar M., Tabatabaei F., Bradley R., et al., “Mechanistic Support of Traditional Persian Medicine for the Treatment of Acne Vulgaris: A Scoping Review,” Journal of Cosmetic Dermatology 21, no. 6 (2022): 2338–2348. [DOI] [PubMed] [Google Scholar]
- 56. Dorni A. C., Amalraj A., Gopi S., Varma K., and Anjana S., “Novel Cosmeceuticals From Plants—An Industry Guided Review,” Journal of Applied Research on Medicinal and Aromatic Plants 7 (2017): 1–26. [Google Scholar]
- 57. Akaberi M., Iranshahy M., and Iranshahi M., “Review of the Traditional Uses, Phytochemistry, Pharmacology and Toxicology of Giant Fennel (Ferula communis L. Subsp. Communis),” Iranian Journal of Basic Medical Sciences 18, no. 11 (2015): 1050. [PMC free article] [PubMed] [Google Scholar]
- 58. Garzoli S., Alarcón‐Zapata P., Seitimova G., et al., “Natural Essential Oils as a New Therapeutic Tool in Colorectal Cancer,” Cancer Cell International 22, no. 1 (2022): 407. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59. Nam J. H. and Lee D.‐U., “ Foeniculum vulgare Extract and Its Constituent, Trans‐Anethole, Inhibit UV‐Induced Melanogenesis via ORAI1 Channel Inhibition,” Journal of Dermatological Science 84, no. 3 (2016): 305–313. [DOI] [PubMed] [Google Scholar]
- 60. Yokota T., Nishio H., Kubota Y., and Mizoguchi M., “The Inhibitory Effect of Glabridin From Licorice Extracts on Melanogenesis and Inflammation,” Pigment Cell Research 11, no. 6 (1998): 355–361. [DOI] [PubMed] [Google Scholar]
- 61. Gupta R., Saxena R., Patidar A., Chourasiya Y., and Malviya N., “Review on Antityrosinase Activity of Some Indian Medicinal Plants and Their Phytoconstituents,” Journal of Drug Delivery and Therapeutics 10 (2020): 199–204. [Google Scholar]
- 62. Chaita E., Lambrinidis G., Cheimonidi C., et al., “Anti‐Melanogenic Properties of Greek Plants. A Novel Depigmenting Agent From Morus alba Wood,” Molecules 22, no. 4 (2017): 514. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63. Uto T., Ohta T., Yamashita A., Fujii S., and Shoyama Y., “Liquiritin and Liquiritigenin Induce Melanogenesis via Enhancement of p38 and PKA Signaling Pathways,” Medicine 6, no. 2 (2019): 68. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64. Cerulli A., Masullo M., Montoro P., and Piacente S., “Licorice ( Glycyrrhiza glabra , G. uralensis , and G. inflata ) and Their Constituents as Active Cosmeceutical Ingredients,” Cosmetics 9, no. 1 (2022): 7. [Google Scholar]
- 65. Heydarirad G., Choopani R., Pasalar M., Parvizi M. M., Hajian P., and Mirzaei H. R., “The Effect of a Chickpea‐Based Persian Diet on Cancer‐Related Fatigue in Breast Cancer Patients: A Semi‐Experimental Study,” Complementary Medicine Research 26, no. 6 (2019): 390–397. [DOI] [PubMed] [Google Scholar]
- 66. Ahmadi N., Mokaberinejad R., Saeidi A., Zandi A., Leach M. J., and Pasalar M., “The Effect of Chickpea Broth on Knee Osteoarthritis—A Pilot Non‐randomised Open‐Labeled Clinical Study,” Advances in Integrative Medicine 7, no. 3 (2020): 121–125. [Google Scholar]
- 67. Mukherjee P. K., Biswas R., Sharma A., Banerjee S., Biswas S., and Katiyar C., “Validation of Medicinal Herbs for Anti‐Tyrosinase Potential,” Journal of Herbal Medicine 14 (2018): 1–16. [Google Scholar]
- 68. Zhang H., Chen F., Wang X., and Yao H.‐Y., “Evaluation of Antioxidant Activity of Parsley ( Petroselinum crispum ) Essential Oil and Identification of Its Antioxidant Constituents,” Food Research International 39, no. 8 (2006): 833–839. [Google Scholar]
- 69. Mahjour M., Tavakkoli Kakhki M., and Feyzabadi Z., “A Review on Oral Herbal Drugs Affecting Chloasma Based on Persian Medicine and Conventional Medicine,” Iranian Journal of Obstetrics, Gynecology and Infertility 22, no. 1 (2019): 60–68. [Google Scholar]
- 70. Katiyar S., Saify K., Singh S. K., and Rai M., “Botanical Study of Skin Lightening Agents,” International Journal of Pharmacognosy 1, no. 4 (2014): 243–249. [Google Scholar]
- 71. Zaidi K. U., Ali S. A., Ali A., and Naaz I., “Natural Tyrosinase Inhibitors: Role of Herbals in the Treatment of Hyperpigmentary Disorders,” Mini Reviews in Medicinal Chemistry 19, no. 10 (2019): 796–808. [DOI] [PubMed] [Google Scholar]
- 72. Nesterov A., Zhao J., and Jia Q., “Natural Tyrosinase Inhibitors for Skin Hyperpigmentation,” Drugs of the Future 33, no. 11 (2008): 945–954. [Google Scholar]
- 73. Kothapalli L., Bhosale K., Thomas A., and Sawant P., “Potential of Herbal Extracts as Sunscreens and Antihyperpigmentation Treatment,” Current Drug Therapy 18, no. 5 (2023): 377–390. [Google Scholar]
- 74. Parvizi M. M., Saki N., Samimi S., Radanfer R., Shahrizi M. M., and Zarshenas M. M., “Efficacy of Castor Oil Cream in Treating Infraorbital Hyperpigmentation: An Exploratory Single‐Arm Clinical Trial,” Journal of Cosmetic Dermatology 23, no. 3 (2024): 911–917. [DOI] [PubMed] [Google Scholar]
- 75. Merecz‐Sadowska A., Sitarek P., Stelmach J., Zajdel K., Kucharska E., and Zajdel R., “Plants as Modulators of Melanogenesis: Role of Extracts, Pure Compounds and Patented Compositions in Therapy of Pigmentation Disorders,” International Journal of Molecular Sciences 23, no. 23 (2022): 14787. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76. Farhan M., “The Promising Role of Polyphenols in Skin Disorders,” Molecules 29, no. 4 (2024): 865. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77. Dong D., Chen S., Feng C., Xiong H., and Xu X., “NB‐UVB Induces Melanocytic Differentiation of Human Hair Follicle Neural Crest Stem Cells,” Annals of Dermatology 32, no. 4 (2020): 289–297. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78. Bastonini E., Kovacs D., and Picardo M., “Skin Pigmentation and Pigmentary Disorders: Focus on Epidermal/Dermal Cross‐Talk,” Annals of Dermatology 28, no. 3 (2016): 279–289. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restriction.
